undamentalytics Newsletter
Sign in

Taysha Gene Therapies, Inc. cash flow statement

In fiscal 2025, Taysha Gene Therapies, Inc.'s operations generated −$93.1m of cash; it spent $738,000 on capital projects, leaving free cash flow of −$93.8m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash from operations−88−73−81−93−132
Depreciation and amortisation11111
Stock-based pay188131318
Capital spending214010
Free cash flow−109−77−82−94−133
Free cash flow after stock pay−127−85−95−107−151
Shares issued—1———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IMRN vs TSHAIVA vs TSHAANL vs TSHACGON vs TSHA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Taysha Gene Therapies, Inc.